"Those with the highest burden of comorbidity had over a 30% increased risk of having disability worsening," Salter said. "In ...

Rutgers Health researchers will enroll primary or secondary progressive multiple sclerosis (p-MS) patients to see if an ...

Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...

Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology is used for the treatment of relapsing multiple sclerosis and ...

The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS ...

TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find ...

DAYBREAK was a Phase 3, multi-center, long-term open-label extension study to evaluate the safety and efficacy of Zeposia (ozanimod) administered orally to patients with relapsing forms of multiple ...

Today is an important day for Cardarelli as it inaugurates a department dedicated to patients with multiple sclerosis. We ...

New Novartis data in relapsing MS reinforce benefits of Kesimpta for first-line and switch patients: Basel Friday, September 20, 2024, 12:00 Hrs [IST] Novartis announced new data ...

Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell ...

The research, presented today at ECTRIMS 2024, is the result of efforts by the Alliance for Research in Hispanic MS (ARHMS) Consortium and is the first large-scale study to identify ancestry-specific ...